When hepatitis B virus meets interferons
G Tan, H Song, F Xu, G Cheng - Frontiers in microbiology, 2018 - frontiersin.org
Chronic hepatitis B virus (HBV) infection imposes a severe burden on global public health.
Currently, there are no curative therapies for millions of chronic HBV-infected patients …
Currently, there are no curative therapies for millions of chronic HBV-infected patients …
Interferon and hepatitis B: current and future perspectives
J Ye, J Chen - Frontiers in Immunology, 2021 - frontiersin.org
Chronic hepatitis B virus (HBV) infection remains a major health burden worldwide for which
there is still no effective curative treatment. Interferon (IFN) consists of a group of cytokines …
there is still no effective curative treatment. Interferon (IFN) consists of a group of cytokines …
Interferon and interferon-stimulated genes in HBV treatment
Q Li, B Sun, Y Zhuo, Z Jiang, R Li, C Lin, Y Jin… - Frontiers in …, 2022 - frontiersin.org
Human hepatitis B virus (HBV) is a small enveloped DNA virus with a complex life cycle. It is
the causative agent of acute and chronic hepatitis. HBV can resist immune system …
the causative agent of acute and chronic hepatitis. HBV can resist immune system …
Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies
N Isorce, J Lucifora, F Zoulim, D Durantel - Antiviral research, 2015 - Elsevier
Chronic hepatitis B virus (HBV) infection remains a major challenge for clinicians, as there
are only two types of approved therapies: interferon-alpha (IFN-α) or its pegylated form, Peg …
are only two types of approved therapies: interferon-alpha (IFN-α) or its pegylated form, Peg …
[HTML][HTML] Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways
RJ Pei, XW Chen, MJ Lu - World journal of gastroenterology: WJG, 2014 - ncbi.nlm.nih.gov
Hepatitis B virus (HBV) infection is one of the major causes of liver diseases, affecting more
than 350 million people worldwide. The interferon (IFN)-mediated innate immune responses …
than 350 million people worldwide. The interferon (IFN)-mediated innate immune responses …
The progress of molecules and strategies for the treatment of HBV infection
Y Pan, H Xia, Y He, S Zeng, Z Shen… - Frontiers in Cellular and …, 2023 - frontiersin.org
Hepatitis B virus infections have always been associated with high levels of mortality. In
2019, hepatitis B virus (HBV)-related diseases resulted in approximately 555,000 deaths …
2019, hepatitis B virus (HBV)-related diseases resulted in approximately 555,000 deaths …
IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome
L Belloni, L Allweiss, F Guerrieri… - The Journal of …, 2012 - Am Soc Clin Investig
HBV infection remains a leading cause of death worldwide. IFN-α inhibits viral replication in
vitro and in vivo, and pegylated IFN-α is a commonly administered treatment for individuals …
vitro and in vivo, and pegylated IFN-α is a commonly administered treatment for individuals …
Functional comparison of interferon‐α subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon‐α and interferon‐γ signaling
Background and Aims Interferon (IFN)‐α, composed of numerous subtypes, plays a crucial
role in immune defense. As the most studied subtype, IFN‐α2 has been used for treating …
role in immune defense. As the most studied subtype, IFN‐α2 has been used for treating …
Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients
S Phillips, S Mistry, A Riva, H Cooksley… - Frontiers in …, 2017 - frontiersin.org
IFN-lambda (IFNλ) is a member of the type III IFN family and is reported to possess anti-
pathogen, anti-cancer, and immunomodulatory properties; however, there are limited data …
pathogen, anti-cancer, and immunomodulatory properties; however, there are limited data …
Hepatitis B virus–host interactions and novel targets for viral cure
G Ligat, ER Verrier, M Nassal, TF Baumert - Current opinion in virology, 2021 - Elsevier
Chronic infection with HBV is a major cause of advanced liver disease and hepatocellular
carcinoma. Nucleos (t) ide analogues effectively control HBV replication but viral cure is …
carcinoma. Nucleos (t) ide analogues effectively control HBV replication but viral cure is …